Beta Bionics (NASDAQ:BBNX) Insider Mark Hopman Sells 775 Shares of Company Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 775 shares of Beta Bionics stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $17.35, for a total value of $13,446.25. Following the sale, the insider directly owned 55,334 shares of the company’s stock, valued at $960,044.90. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Mark Hopman also recently made the following trade(s):

• On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The stock was sold at an average price of $18.96, for a total transaction of $7,015.20.
• On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The stock was sold at an average price of $20.13, for a total transaction of $619,581.27.
• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total transaction of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $101,798.97.

Beta Bionics Stock Down 5.5%

Shares of NASDAQ:BBNX traded down $0.96 during midday trading on Friday, reaching $16.35. The company’s stock had a trading volume of 660,832 shares, compared to its average volume of 1,051,882. The firm has a market capitalization of $735.59 million, a PE ratio of -9.91 and a beta of 3.39. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The stock has a fifty day moving average of $19.04 and a 200 day moving average of $15.19.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The company had revenue of $32.01 million during the quarter. Sell-side analysts anticipate that Beta Bionics, Inc. will post -2.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on BBNX. Wells Fargo & Company began coverage on Beta Bionics in a report on Wednesday, September 23rd. They set an “overweight” rating and a $28.00 target price on the stock. William Blair started coverage on Beta Bionics in a report on Friday, August 21st. They issued a “market perform” rating for the company. Bank of America upped their price objective on Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 15th. UBS Group restated a “buy” rating and issued a $25.00 price objective on shares of Beta Bionics in a research report on Tuesday, September 15th. Finally, Wall Street Zen raised shares of Beta Bionics from a “sell” rating to a “hold” rating in a research note on Saturday, September 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Beta Bionics currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Institutional Investors Weigh In On Beta Bionics

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new position in Beta Bionics in the 2nd quarter worth about $52,340,000. Eversept Partners LP purchased a new position in Beta Bionics during the fourth quarter worth approximately $20,667,000. 12 West Capital Management LP acquired a new stake in Beta Bionics in the fourth quarter valued at approximately $17,520,000. Bank of America Corp DE acquired a new stake in Beta Bionics in the second quarter valued at approximately $8,566,000. Finally, Perceptive Advisors LLC grew its holdings in Beta Bionics by 39.8% in the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock valued at $8,446,000 after purchasing an additional 240,000 shares during the period.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Negative Sentiment: The securities lawsuit covers investors who purchased Beta Bionics shares between July 30, 2025, and February 24, 2026. The claims reportedly relate to alleged disclosures concerning the FDA’s concerns about the company’s iLet automated insulin-delivery system and the impact of those revelations on the stock. The allegations have not been proven. Hagens Berman securities class-action announcement
• Negative Sentiment: Additional notices cite allegations that Beta Bionics abandoned a safety feature in the iLet dosing algorithm and failed to investigate more than 18,000 customer complaints. If substantiated, such claims could increase regulatory, litigation, and reputational risks for the company. SueWallSt Beta Bionics lawsuit notice
• Negative Sentiment: The high volume of investor-law-firm announcements keeps attention focused on legal exposure and prior share-price losses, weighing on investor confidence. The lead-plaintiff deadline is November 3, 2026. Kaplan Fox lead-plaintiff deadline notice
• Neutral Sentiment: Insider Mark Hopman sold 775 shares for approximately $13,446, reducing his direct ownership by 1.38%. Because the sale was small relative to his remaining 55,334 shares, it is a modest signal but may add some pressure to sentiment. SEC insider transaction filing

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.